Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 6/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 3/20 | 0.35 |
| ▸ | JAK3 | P52333 | 3/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4474865 | 0.97 | MTOR (0.42) | MTORPIK3CANR1H2NR1H3NAMPT | |
| SCHEMBL5613807 | 0.94 | MTOR (0.36) | MTORPIK3CANR1H2NR1H3NAMPT | |
| SCHEMBL5613809 | 0.91 | MTOR (0.38) | MTORPIK3CANR1H2NR1H3NAMPT | |
| SCHEMBL3489517 | 0.90 | ESR2 (0.45) | MTORPIK3CANR1H2NAMPTTMEM97 | |
| SCHEMBL3489514 | 0.89 | ESR2 (0.46) | MTORPIK3CANR1H2NR1H3NAMPT | |
| SCHEMBL3486731 | 0.81 | TMPRSS2 (0.38) | NAMPTTMEM97SIGMAR1JAK2ALDH1A1 | |
| SCHEMBL3486729 | 0.80 | TMPRSS2 (0.38) | NR1H2NR1H3NAMPTTMEM97SIGMAR1 | |
| SCHEMBL3488135 | 0.79 | ACVR1 (0.42) | NR1H2NR1H3NAMPTTMEM97SIGMAR1 | |
| SCHEMBL3487580 | 0.79 | NR1H2 (0.54) | NR1H2NR1H3JAK2ALDH1A1MAPT | |
| SCHEMBL3488550 | 0.78 | NPC1 (0.38) | NAMPTJAK2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | MTOR 1667/4885PIK3CA 1380/4885NR1H2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.